

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-124 (Cancelled)

125. (New) The compound Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH₂, or a pharmaceutically acceptable salt thereof.

126. (New) A pharmaceutical composition comprising Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH₂, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

127. (New) A method of preventing or treating a condition associated with complement activation and/or where the inhibition of the complement system leads to a relief of symptoms in a patient in need of such prevention, treatment or relief, comprising administering an effective amount of a medicament Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH₂ to said patient.

128. (New) The method according to claim 127, wherein the condition is such that the inhibition of the C5a receptor by Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH₂ alone or in combination with other therapeutics leads to a relief of the symptoms.

129. (New) The method according to claim 127, wherein the condition and/or the symptoms to be treated are selected from the group comprising autoimmune diseases, acute inflammatory diseases, trauma, local inflammations, shock and burn.

130. (New) The method according to claim 127, wherein the condition is selected from the group comprising rheumatoid arthritis, ankylosis spodylitis, sarcoidosis, systemic lupus erythematosus, multiple sclerosis, psoriasis, septic shock, haemorrhagic shock, systemic inflammatory response syndrome (SIRS), multiple organ failure (MOF), asthma, vasculitis,

myocarditis, dermatomyositis, inflammatory bowel disease (IBD), pemphigus, myasthenia gravis, glomerulonephritis, acute respiratory insufficiency, stroke, myocardial infarction, reperfusion injury, neurocognitive dysfunction, anti-phospholipid syndrome, burn, inflammatory diseases of the eye, local manifestations of systemic diseases, inflammatory diseases of the vasculature, and acute injuries of the central nervous system.

131. (New) The method according to claim 127, wherein the inflammatory disease of the eye is selected from the group comprising uveitis, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, ocular pemphigoid, keratoconjunctivitis, Stevens-Johnson syndrome, and Graves ophthalmopathy.

132. (New) The method according to claim 127, wherein the condition is a local manifestation of a systemic disease, whereby the systemic disease is selected from the group comprising rheumatoid arthritis, SLE, type I diabetes, and type II diabetes.

133. (New) The method according to claim 127, wherein the manifestations are selected from the group comprising manifestations at the eye, at or in the brain, at the vessels, at the heart, at the lung, at the kidneys, at the liver, at the gastro-intestinal tract, at the spleen, at the skin, at the skeletal system, at the lymphatic system, and in the blood.

134. (New) The method according to claim 127, wherein the inflammatory disease of vasculature is selected from the group comprising vasculitis, vascular leakage, and atherosclerosis.

135. (New) The method according to claim 127, wherein the medicament is used for the prevention and/or the support of surgery.

136. (New) The method according to claim 127, wherein the medicament is used for the prevention and/or support and/or post-operative treatment of a surgery, whereby the surgery is selected from the group comprising CABG, PACT, PTA, MidCAB, OPCAB, thrombolysis, organ transplantation, and vessel clamping.

137. (New) The method according to claim 127, wherein the medicament is used for thrombolytic treatment.

138. (New) The method according to claim 127, wherein the medicament is used in the settings of dialysis therapy, optionally before, during, and/or after such therapy.

139. (New) The method according to claim 127, wherein the medicament is used for the prevention of organ damage of a transplanted organ or of an organ to be transplanted.

140. (New) The method according to claim 127, wherein the medicament is used for the prevention or treatment of transplant rejection.